TABLE 2.
Frequencies of CCR2-CCR5 haplotypes and genotypes in HEPS and HIV-1 SCs from the MACS, the DCG Study, and the SFMHS
| No. (%) with haplotype or genotype givena
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Haplotype or genotype | MACS
|
DCG
|
SFMHS
|
||||||
| Caucasians (n = 90 HEPS + 469 SCs)
|
African-Americans (n = 44 SCs)
|
Caucasians (n = 95 SCs)
|
Caucasians (n = 49 SCs)
|
||||||
| HEPS | All SCs | Selected SCs | All | Selected | All | Selected | All | Selected | |
| Haplotype | 2n = 180 | 2n = 938 | 2n = 682 | 2n = 88 | 2n = 62 | 2n = 190 | 2n = 78 | 2n = 98 | 2n = 74 |
| A | 17 (9) | 88 (9) | 61 (9) | 22 (25) | 14 (23) | 23 (12) | 12 (15) | 11 (9) | 5 (7) |
| C | 63 (35) | 332 (34) | 239 (35) | 12 (14) | 10 (16) | 71 (37) | 25 (32) | 35 (36) | 29 (39) |
| D | 2 (1) | 2 (<1) | 0 | 15 (17) | 10 (16) | 0 | 0 | 0 | 0 |
| E | 49 (27) | 296 (32) | 215 (32) | 15 (17) | 10 (16) | 61 (32) | 28 (36) | 31 (31) | 22 (30) |
| F*1 | 0 | 2 (<1) | 2 (<1) | 3 (3) | 2 (3) | 3 (2) | 0 | 0 | 0 |
| F*2(64I) | 16 (9) | 90 (10) | 69 (10) | 14 (16) | 11 (18) | 14 (7) | 2 (3) | 7 (7) | 7 (9) |
| G*1 | 12 (7) | 33 (4) | 24 (4) | 3 (3) | 2 (3) | 3 (2) | 2 (3) | 2 (2) | 2 (3) |
| G*2 (Δ32) | 21 (12) | 86 (9) | 66 (10) | 2 (2) | 1 (2) | 15 (8) | 9 (12) | 11 (11) | 8 (11) |
| Unresolved | 0 | 9 (1) | 6 (1) | 2 (2) | 2 (3) | 0 | 1 (1) | 1 (1) | |
| Genotypeb | n = 90 | n = 469 | n = 341 | n = 44 | n = 31 | n = 95 | n = 39 | n = 49 | n = 37 |
| A/A | 0 | 7 (1) | 5 (1) | 2 (5) | 2 (6) | 2 (2) | 2 (5) | 2 (4) | 1 (3) |
| A/C | 3 (3) | 26 (6) | 14 (4) | 1 (2) | 0 | 9 (9) | 4 (10) | 2 (4) | 1 (3) |
| A/E | 4 (4) | 27 (6) | 20 (6) | 3 (7) | 0 | 7 (7) | 2 (5) | 2 (4) | 1 (3) |
| A/F*2 | 4 (4) | 8 (2) | 5 (1) | 4 (9) | 3 (10) | 0 | 0 | 0 | 0 |
| A/G*2 | 6 (7) | 12 (3) | 11 (3) | 1 (2) | 1 (3) | 3 (3) | 2 (5) | 3 (6) | 1 (3) |
| C/C | 11 (12) | 58 (12) | 44 (13) | 1 (2) | 1 (3) | 13 (14) | 4 (10) | 3 (6) | 3 (8) |
| C/E | 22 (24) | 102 (22) | 72 (21) | 1 (2) | 1 (3) | 21 (22) | 10 (26) | 17 (34) | 14 (38) |
| C/F*2 | 4 (4) | 31 (7) | 26 (8) | 4 (9) | 4 (13) | 7 (7) | 0 | 3 (6) | 1 (3) |
| C/G*1 | 5 (6) | 14 (3) | 9 (3) | 1 (2) | 1 (3) | 0 | 0 | 0 | 0 |
| C/G*2 | 7 (8) | 36 (8) | 26 (8) | 0 | 0 | 6 (6) | 3 (8) | 5 (10) | 3 (8) |
| E/E | 5 (6) | 56 (12) | 39 (11) | 3 (7) | 3 (10) | 9 (9) | 5 (13) | 4 (8) | 4 (10) |
| E/F*2 | 3 (3) | 23 (5) | 19 (6) | 2 (5) | 2 (6) | 7 (7) | 2 (5) | 2 (4) | 0 |
| E/G*1 | 3 (3) | 11 (2) | 9 (3) | 0 | 0 | 2 (2) | 1 (3) | 0 | 0 |
| E/G*2 | 7 (8) | 21 (4) | 17 (5) | 0 | 0 | 5 (5) | 3 (8) | 2 (4) | 2 (5) |
| F*2/F*2 | 1 (1) | 6 (1) | 3 (1) | 0 | 0 | 0 | 0 | 0 | 0 |
| F*2/G*2 | 1 (1) | 12 (2) | 9 (3) | 1 (2) | 0 | 0 | 0 | 1 (2) | 1 (3) |
| Others | 4 (4) | 18 (4) | 13 (4) | 20 (45)c | 13 (42)c | 4 (4) | 1 (3) | 2 (4) | 5 (14) |
a
Criteria for All: CCR typing and clinical outcome data available; criteria for selected, criteria for All plus seroconversion ≤12 months and having ≥1 measurement of HIV-1 RNA level at various intervals (see text and Table 1).
b
Genotypes shown here are found in ≥5 (1%) MACS SCs.
c
Mostly consisting of genotypes involving haplotype D (i.e., A/D, C/D, D/D, D/E, and D/F*2).